Latest Headlines

  1. Anti-MTBR (Microtubule Binding Region) Tau Antibody Etalanetug Granted FDA Fast Track Designation 9/18/2025

    Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

  2. Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (CKD) 9/17/2025

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD).

  3. Rubedo Life Sciences Announces U.S. FDA Clearance Of IND For Selective GPX4 Modulating Lead Drug Candidate RLS-1496 For Actinic Keratosis, Expands Clinical Advisory Board 9/17/2025

    Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis.

  4. Adagene Expands SAFEbody® Collaboration And License Agreement With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate 9/16/2025

    Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.

  5. Dr. Reddy's Launches Novel Molecule 'Tegoprazan' In India 9/16/2025

    Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of the novel molecule ‘Tegoprazan’, for acid-related gastrointestinal diseases in India. Dr. Reddy’s launches Tegoprazan (50 mg) under the brand name PCAB.

  6. New Drug Lowers Treatment-Resistant High Blood Pressure And May Slow Kidney Disease 9/16/2025

    A new drug has shown unprecedented promise in lowering blood pressure and preventing the progression of kidney disease for people with hard-to-treat hypertension. The medication, baxdrostat, reduces the levels of a hormone that drives high blood pressure and could transform hypertension care.

  7. New AI Molecular Prediction Model Could Speed Up Drug Discovery 9/15/2025

    Innovative research conducted in collaboration between a graduate student here and the global biopharmaceutical leader AstraZeneca has led to an important advancement in the field of AI-assisted drug discovery.

  8. Mycenax And SPERA PHARMA Forge Strategic Alliance To Streamline ADC Drug Substance And Drug Product Manufacturing Services 9/15/2025

    Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based expert in pharmaceutical Chemistry, Manufacturing, and Controls (CMC).

  9. Queen Mary Trials New Approach To Drug Development For Rare Diseases 9/11/2025

    Developing disease modifying therapies for rare diseases is extremely challenging. It’s clinically difficult due to the small cohort sizes, and it’s difficult to raise investment as the market may not be big enough to cover the costs.

  10. GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform To Transform Precision Medicine And Drug Development 9/11/2025

    GNQ Insilico Inc. (“GNQ” or “the Company”), a pioneering TechBio firm leveraging exponential technologies for precision medicine, announces the official launch of its groundbreaking deep tech Drug Assessment Platform (DAP).